Universitätsklinikum Carl Gustav Carus Dresden

Evidence for postnatal neurogenesis in the human amygdala (2022) Röder S, Burkardt P, Rost F, Rode J, Brusch L, Coras R, Englund E, et al. Journal article Intracranial hemorrhage in COVID-19 patients during extracorporeal membrane oxygenation for acute respiratory failure: a nationwide register study report (2022) von Stillfried S, Bülow RD, Röhrig R, Meybohm P, Boor P, Böcker J, Schmidt J, et al. Journal article Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registry (2022) Blank N, Schmalzing M, Moinzadeh P, Oberste M, Siegert E, Mueller-Ladner U, Riemekasten G, et al. Journal article Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial (2022) Roellig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Haenel M, et al. Conference contribution Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis (2022) Unglaub JM, Schlenk RF, Hanoun M, Reinhardt HC, Middeke JM, Schaefer-Eckart K, Steffen B, et al. Conference contribution Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome (2022) Georgi JA, Stasik S, Zukunft S, Hartwig M, Roellig C, Oelschlaegel U, Krug U, et al. Conference contribution Outcome of 841 Older Patients (> 55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols (2022) Goekbuget N, Viardot A, Steffen B, Hahn J, Spriewald B, Martin S, Raffel S, et al. Conference contribution In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial (2022) Stelljes M, Middeke JM, Bug G, Wagner EM, Mueller LP, Christoph S, Krause S, et al. Conference contribution Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (> 55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) (2022) Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, et al. Conference contribution S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid (2022) Hofmann SC, Gunther C, Bockle BC, Didona D, Ehrchen J, Gaskins M, Geerling G, et al. Journal article